Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach

被引:3
|
作者
Dulai, Parambir S. [1 ]
Siegel, Corey A. [2 ]
机构
[1] Univ Calif San Diego, San Diego, CA 92103 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
关键词
Crohn's disease; ulcerative colitis; risk; adverse events; inflammatory bowel disease; infections; NONMELANOMA SKIN-CANCER; FACTOR-ALPHA ANTAGONISTS; CROHNS-DISEASE; INCREASED RISK; HEPATITIS-B; CLOSTRIDIUM-DIFFICILE; COMBINATION THERAPY; OPPORTUNISTIC INFECTIONS; MAINTENANCE THERAPY; RECEIVE THIOPURINES;
D O I
10.2174/1389450118666170525114939
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Treatment strategies and treatment options have changed considerably over the past decade for Inflammatory Bowel Disease (IBD). Alongside this shift in therapeutic options has come an opportunity to personalize treatment decisions based on individual patient profiles and preferences. One of the most important aspects of therapy in IBD is treatment related risk, and an opportunity exists to personalize therapy through optimization of drug safety profiles in individual patients. In this review we discuss the potential risks of therapy in IBD, opportunities to mitigate those risks, and a personalized approach to consider when using these agents in clinical practice.
引用
收藏
页码:740 / 747
页数:8
相关论文
共 50 条
  • [1] Safety profile of methotrexate in inflammatory bowel disease
    Gabbani, Tommaso
    Deiana, Simona
    Lunardi, Sarah
    Manetti, Natalia
    Annese, Vito
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) : 1427 - 1437
  • [2] Inflammatory Bowel Disease: A Personalized Approach
    Konidari, Anastasia
    Dickens, David
    Pirmohamed, Munir
    FRONTIERS IN PEDIATRICS, 2021, 8
  • [3] Safety considerations with biologics and new inflammatory bowel disease therapies
    Queiroz, Natalia S. F.
    Regueiro, Miguel
    CURRENT OPINION IN GASTROENTEROLOGY, 2020, 36 (04) : 257 - 264
  • [4] Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events
    Khanna, Reena
    Feagan, Brian G.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) : 987 - 997
  • [5] Medical Management of Inflammatory Bowel Disease in the Elderly: Balancing Safety and Efficacy
    Ha, Christina Y.
    CLINICS IN GERIATRIC MEDICINE, 2014, 30 (01) : 67 - +
  • [6] Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies
    Bhat, Shubha
    Click, Benjamin
    Regueiro, Miguel
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (05) : 829 - 843
  • [7] Treatments of inflammatory bowel disease toward personalized medicine
    Kim, Ki-Uk
    Kim, Jisu
    Kim, Wan-Hoon
    Min, Hyeyoung
    Choi, Chang Hwan
    ARCHIVES OF PHARMACAL RESEARCH, 2021, 44 (03) : 293 - 309
  • [8] Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
    Di Paolo, Antonello
    Luci, Giacomo
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [9] Efficacy and Safety of Vedolizumab in Patients with Inflammatory Bowel Disease in Association with Vedolizumab Drug Levels
    Huettemann, Eva
    Muzalyova, Anna
    Groehl, Katharina
    Nagl, Sandra
    Fleischmann, Carola
    Ebigbo, Alanna
    Classen, Johanna
    Wanzl, Julia
    Prinz, Friederike
    Mayr, Patrick
    Schnoy, Elisabeth
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (01)
  • [10] Can Surgery for Inflammatory Bowel Disease be Personalized?
    Spinelli, Antonino
    Marano, Alessandra
    Bacchelli, Claudio
    Mariani, Nicola Maria
    Montorsi, Marco
    Kotze, Paulo Gustavo
    CURRENT DRUG TARGETS, 2018, 19 (07) : 798 - 804